— This is the script of CNBC's news report for China's CCTV on June 30, Monday.
Welcome to the CNBC Business Daily.
We head into the second half of the year with a look at what to expect in various sectors.
CNBC's Josh Lipton explains what's on the docket for the tech industry amid concerns of another bubble potentially forming.
Here's what to watch in the tech sector in the second half. There are nearly 2 billion smartphone users in the world, and you might have a few more options deciding what your next device should be. Amazon will ship it's new phone on july 25th and apple is expected to launch it's new smartphone sometime in the fall. Another trend to watch, tech companices could deliver more devices to track your health. Apple just launched a new app called "Health. The tech titans move into this area could motivate other companies to jump into this space as well.
Switching to Enterprise, analysts think they will see a pick up in deal-making in the second half. Large vendors are going to be looking to acquire more companies to build out the solutions they can offer to clients from storage to cloud services. That's your second half tech outlook, I'm Josh Lipton.
And now we turn our attention to the Biotech space... where Meg Tirrell looks ahead to what could shape the future of pharmaceuticals.
Here's what to watch for in Biotech and Pharma in the second half. The Hepatitis C space will continue to be hot. With Gilead expected to receive approval of a potent drug combination in October. And more data will be presented on drugs from Merck, Bristol-Myers and Abbvie at the meeting in November.
Among biotechs, expect data read outs form Biogen, Intercept and others on important pipeline products that could have big implications for the stocks. And never discount M&A. It's already been a record year and analysts expect that only to continue.
Valeant is pursuing a hostile bid for botox maker Allergan. And the second half's biggest deal may in fact be a rerun of the first half's. Analysts expect Prizer to make another run at buying AstraZeneca.
That's your second half Pharma and Biotech outlook. I'm Meg Tirell.
Fines, regulation, and the constant need to keep profits up - those are all the challenges banks have had to face.
How will the sector do in H2?
CNBC's Kayla Tausche takes a look.
Here's what to watch for in the financial sector in the second half. Polls will see bank earnings improve alongside the economy. Consumer banks will see loan demand keep picking up. The Fed's wagebook having shown strength in all US districts. And investmen banks will reapbig paydays as deals from this M&A boom begin to close. Costs though will rise at the same time, bond trading remaining weak and the fed may stop paying interest or may even charge banks for the 2.6 trillion dollars in excess reserves they hold. Finally BNP Paribas, Bank of America and Citigroup could yet pay tens of billions of dollars to settle legal issues. That's your second half financials outlook, I'm Kayla Tausche.
That wraps up this edition of the Business Daily.
I'm Sri Jegarajah, reporting from CNBC's Asian headquarters.